Quantcast

Latest Prostate-specific antigen Stories

2014-08-07 16:28:34

17% Increase in Test Volume, 11% Increase in Total Revenue and 29% Increase in International Product Revenue Compared to Prior Year REDWOOD CITY, Calif., Aug. 7, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2014. Product revenue was $70.5 million in the second quarter of 2014, compared with $63.7 million for the second quarter of 2013, an increase of 11 percent. There was no contract revenue in...

2014-08-06 08:31:58

Study Achieved Primary Endpoint of Predicting Recurrence after Surgery and Reconfirmed Original Adverse Pathology Endpoint from Published UCSF Validation Study REDWOOD CITY, Calif., Aug. 6, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX(®) Genomic Prostate Score (GPS) predicts...

2014-08-05 12:31:41

Active Surveillance Provides Low-Risk Patients Less Harmful Treatment Option NORTHFIELD, Ill., Aug. 5, 2014 /PRNewswire-USNewswire/ -- Prostate cancer is the second leading cause of cancer death in men in the United States. Active surveillance offers low-risk prostate cancer patients a means to avoid the potentially harmful side effects from treatment. Pathologists help determine patient eligibility for active surveillance and today a multi-specialty team published their recommendations for...

2014-08-05 08:28:20

Demands Manufacturers Prove Claims of Safety and Benefits For Prostate Cancer Treatments CORAL SPRINGS, Fla., Aug. 5, 2014 /PRNewswire/ -- A prominent Florida prostate cancer specialist is leading a groundswell of physicians and prostate cancer patients challenging the efficacy of a popular robotic surgical treatment marketed and promoted into near ubiquitous use in hospitals across the nation. In an extensive article...

2014-07-29 04:22:06

OXFORD, England, July 29, 2014 /PRNewswire/ -- Glide Pharmaceutical Technologies Ltd (Glide Pharma) today announced that it has taken an exclusive worldwide licence to an innovative prostate cancer diagnostic technology from FScan Ltd, a Durham University spin-out company. Under the terms of the agreement, Glide Pharma will pay an upfront fee, development and commercial milestone payments, and royalties on future product sales. Glide Pharma has also taken an option for...

2014-07-11 09:19:30

Harvard School of Public Health Vasectomy was associated with a small increased risk of prostate cancer, and a stronger risk for advanced or lethal prostate cancer according to a new study from Harvard School of Public Health (HSPH). The researchers found that the association remained even among men who received regular PSA screening, suggesting the increased risk of lethal cancer cannot be explained by diagnostic bias. It is the largest and most comprehensive study to date to look at the...

2014-06-11 08:31:25

LONDON, June 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Cancer Diagnostic Testing World Marketshttp://www.reportbuyer.com/pharma_healthcare/diagnostics/cancer_diagnostic_testing_world_markets.html Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs...

2014-05-27 23:03:55

Humility of Mary Health Partners will provide free PSA blood draws to check 100 men for prostate cancer during the Fuel the Fight car and motorcycle show June 1 at Boardman High School. Youngstown, Ohio (PRWEB) May 27, 2014 Humility of Mary Health Partners will provide 100 free PSA blood draws to check for prostate cancer during the Fuel the Fight car and motorcycle show June 1 in Boardman. Fuel the Fight, sponsored by the HMHP Foundation and Sweeney Chevrolet, Buick, GMC, benefits Man Up...

2014-05-27 08:27:46

-- High calibre German consulting company appointed to assist CE Mark registration process SYDNEY, May 27, 2014 /PRNewswire/ -- Australian biotechnology company Minomic International Limited will register its MiStat(TM) ELISA prostate cancer test for CE Mark approval in the latter part of 2014. Achieving CE approval will be a key commercial milestone for the company, allowing it to sell and market its early detection diagnostic technology in the 33 member countries within the...

2014-05-17 12:20:17

Panel discusses long-term effect on quality of life ORLANDO, Fla., May 17, 2014 /PRNewswire-USNewswire/ -- A series of studies evaluating the outcomes, benefits, concerns and quality of life of men undergoing active surveillance for prostate cancer will be presented to media at a special press conference during the 2014 Annual Scientific Meeting of the American Urological Association (AUA). Stacy Loeb, MD, assistant professor at New York University, New York, NY, will moderate the session,...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related